Flyer:
Publishable Deliverables:
Work Package 1: Management
- D1.2: Dissemination Materials
- D1.3: 1st imSAVAR Workshop
- D1.4: 2nd imSAVAR Workshop
- D1.5: 3rd imSAVAR Workshop
- D1.9: Summary of Patient Engagement
- D1.12: Involvement of Regulatory Agencies
Work Package 2: Immuno-oncology models
- D2.1: Preliminary irAOP – CAR-T & BiTE MoAs
- D2.2: Preliminary irAOP – CPI MoA
- D2.3: CAR-T & BiTE immune safety assessment research roadmap
- D2.4: CPI immune safety assessment research roadmap
- D2.5: 1st iteration in vitro & MPS models
- D2.6: 1st interation refined CRS in vivo models
- D2.7: Strategies and experimental in vivo and in vitro immune-competent target organ models to study the MoA of immune checkpoint inhibitors (CPI)
- D2.8: 2nd iteration in vitro & MPS models
- D2.10: 2nd iteration of strategies and experimental in vivo and in vitro immune-competent target organ models to study the MoA of immune checkpoint inhibitors (CPI)
Work Package 3: Innovative models for safety assessment of immuno-inflammatory disease therapeutics
- D3.1: Preliminary irAOP – IL-2-TREG
- D3.2: TReg-IL2 immune safety assessment research roadmap
- D3.3: 1st iteration in vivo and in vitro model readouts IL-2 MoA
- D3.4: 1st iteration in vivo and in vitro models IL-2 MoA
Work Package 4: Biomarkers (BMs)
- D4.2: 1st iteration of advanced immune cell profiling
- D4.3: 2nd iteration of advanced immune cell profiling
- D4.5: First iteration to characterize molecular mechanism leading to immune-related adverse events
-
D4.6: Second iteration to characterize molecular mechanisms leading to immune-related adverse events